Ravi Salgia to Hepatocyte Growth Factor
This is a "connection" page, showing publications Ravi Salgia has written about Hepatocyte Growth Factor.
Connection Strength
4.899
-
MET in Lung Cancer: Biomarker Selection Based on Scientific Rationale. Mol Cancer Ther. 2017 04; 16(4):555-565.
Score: 0.581
-
Role of PAX8 in the regulation of MET and RON receptor tyrosine kinases in non-small cell lung cancer. BMC Cancer. 2014 Mar 14; 14:185.
Score: 0.471
-
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol. 2012 Dec; 7(16 Suppl 5):S372-4.
Score: 0.431
-
Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol. 2011 Nov; 6(11 Suppl 4):S1810-1.
Score: 0.399
-
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. J Environ Pathol Toxicol Oncol. 2009; 28(2):89-98.
Score: 0.328
-
Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion. Br J Cancer. 2007 Aug 06; 97(3):368-77.
Score: 0.297
-
Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2007 Jun; 292(6):L1488-94.
Score: 0.289
-
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res. 2006 Jan 01; 66(1):352-61.
Score: 0.267
-
c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett. 2005 Jul 08; 225(1):1-26.
Score: 0.246
-
Haptoglobin alpha-subunit and hepatocyte growth factor can potentially serve as serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2004 Mar-Apr; 24(2C):1031-8.
Score: 0.235
-
Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer. Clin Cancer Res. 2002 Feb; 8(2):620-7.
Score: 0.203
-
Role of c-Met/phosphatidylinositol 3-kinase (PI3k)/Akt signaling in hepatocyte growth factor (HGF)-mediated lamellipodia formation, reactive oxygen species (ROS) generation, and motility of lung endothelial cells. J Biol Chem. 2014 May 09; 289(19):13476-91.
Score: 0.118
-
MET as a possible target for non-small-cell lung cancer. J Clin Oncol. 2013 Mar 10; 31(8):1089-96.
Score: 0.109
-
Critical role of S1PR1 and integrin ß4 in HGF/c-Met-mediated increases in vascular integrity. J Biol Chem. 2013 Jan 25; 288(4):2191-200.
Score: 0.108
-
Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 2011 Dec; 11(12):1655-62.
Score: 0.100
-
Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov. 2011 Dec; 1(7):573-9.
Score: 0.100
-
Fyn is downstream of the HGF/MET signaling axis and affects cellular shape and tropism in PC3 cells. Clin Cancer Res. 2011 May 15; 17(10):3112-22.
Score: 0.095
-
MET and phosphorylated MET as potential biomarkers in lung cancer. J Environ Pathol Toxicol Oncol. 2011; 30(4):341-54.
Score: 0.094
-
CD44 regulates hepatocyte growth factor-mediated vascular integrity. Role of c-Met, Tiam1/Rac1, dynamin 2, and cortactin. J Biol Chem. 2007 Oct 19; 282(42):30643-57.
Score: 0.075
-
Lysophosphatidic acid modulates c-Met redistribution and hepatocyte growth factor/c-Met signaling in human bronchial epithelial cells through PKC delta and E-cadherin. Cell Signal. 2007 Nov; 19(11):2329-38.
Score: 0.074
-
c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res. 2007 Apr 01; 13(7):2246-53.
Score: 0.073
-
c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy. Curr Oncol Rep. 2007 Mar; 9(2):102-8.
Score: 0.072
-
c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev. 2003 Dec; 22(4):309-25.
Score: 0.058
-
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 2002 Feb; 13(1):41-59.
Score: 0.051
-
RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther. 2011 Jul 01; 12(1):9-46.
Score: 0.024